Analysis of information sources in references of the Wikipedia article "วัคซีนโควิด-19 ของไฟเซอร์-ไบออนเทค" in Thai language version.
{{cite book}}
: CS1 maint: uses authors parameter (ลิงก์)the first SARS-CoV-2 viral genomes were shared via GISAID on 10 January 2020
Vaccine goes bad five days after thawing, requires two shots; Many nations face costly ramp up of cold-chain infrastructure
{{cite web}}
: CS1 maint: url-status (ลิงก์)WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
{{cite journal}}
: Cite journal ต้องการ |journal=
(help); ตรวจสอบค่า |doi=
(help)development of BNT162b2 was initiated on 10 January 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
{{cite journal}}
: Cite journal ต้องการ |journal=
(help)development of BNT162b2 was initiated on 10 January 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
{{cite book}}
: CS1 maint: uses authors parameter (ลิงก์)development of BNT162b2 was initiated on 10 January 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
BioNTech struck a collaboration deal with Shanghai Fosun Pharmaceutical over the German biotech firm's rights in China to an experimental coronavirus vaccine, the latest gambit in a global race to halt the pandemic.
BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.
Vaccine goes bad five days after thawing, requires two shots; Many nations face costly ramp up of cold-chain infrastructure
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.